Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Medjkouh L
with no apparent toxicity
administered twice a day by oral gavage for 9-12 days) reduces ex vivo sickling and prolongs red blood cells (RBCs) half-life in a murine model of sickle cell disease (SCD)
Epacadostat-analog
and peak plasma concentration was 58 μM
ABT-492 Size:2mg solid Medjkouh LABT 492 is a non zwitterionic fluoroquinolone antibiotic under development for for the treatment of respiratory and skin infections. Delafloxacin demonstrates excellent antibacterial potency and exhibits a low probability for the selection of resistant mutants in MRSA. Although mutants can be selected at low frequencies in vitro from quinolone resistant isolates, delafloxacin MICs and MPCs remain low and a fitness cost can be observed. Consequently
US$ 211.00
US$ 529.50
US$ 452.50
US$ 693.50
US$ 450.00